Zenuzolac: meta-analysis of COVID-19 studies

All studies Mortality Hospitalization Serious outcomes Recovery RCTs RCT mortality All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−200%

Mortality (1)−200%

Hospitalization (1)1%

RCTs (1)−200%

Late (1)−200%

00.511.5+

← Zenuzolac
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Zenuzolac COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Kane (DB RCT)−200%3.00 · 0.32–28.32death46 (n)44 (n)

Late treatment−200%3.00 · 0.32–28.3246 (n)44 (n)200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.34

All studies−200%3.00 · 0.32–28.3246 (n)44 (n)200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.3400.511.52+

Rotate screen for more detailsIncrease width for more details

← Zenuzolac
reduces riskZenuzolac
increases risk →

c19early.org

October 2026

Zenuzolac COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Kane (DB RCT)−200%3.00 · 0.32–28.3246 (n)44 (n)

Late treatment−200%3.00 · 0.32–28.3246 (n)44 (n)200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.34

All studies−200%3.00 · 0.32–28.3246 (n)44 (n)200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.3400.511.52+

Rotate screen for more detailsIncrease width for more details

← Zenuzolac
reduces riskZenuzolac
increases risk →

c19early.org

October 2026

Zenuzolac COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Kane (DB RCT)1%0.99 · 0.88–1.11hosp. time46 (n)44 (n)

Late treatment1%0.99 · 0.88–1.1146 (n)44 (n)1% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.87

All studies1%0.99 · 0.88–1.1146 (n)44 (n)1% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.8700.511.52+

Rotate screen for more detailsIncrease width for more details

← Zenuzolac
reduces riskZenuzolac
increases risk →

c19early.org

October 2026

Zenuzolac COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Kane (DB RCT)−200%3.00 · 0.32–28.32death46 (n)44 (n)

Late treatment−200%3.00 · 0.32–28.3246 (n)44 (n)200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.34

All studies−200%3.00 · 0.32–28.3246 (n)44 (n)200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.3400.511.52+

Rotate screen for more detailsIncrease width for more details

← Zenuzolac
reduces riskZenuzolac
increases risk →

c19early.org

October 2026

Zenuzolac COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Kane (DB RCT)−1%1.01 · 0.25–4.09no recov.46 (n)44 (n)

Late treatment−1%1.01 · 0.25–4.0946 (n)44 (n)1% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.99

All studies−1%1.01 · 0.25–4.0946 (n)44 (n)1% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.9900.511.52+

Rotate screen for more detailsIncrease width for more details

← Zenuzolac
reduces riskZenuzolac
increases risk →

c19early.org

October 2026

Zenuzolac COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Kane (DB RCT)−200%3.00 · 0.32–28.32death46 (n)44 (n)

Late treatment−200%3.00 · 0.32–28.3246 (n)44 (n)200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.34

All studies−200%3.00 · 0.32–28.3246 (n)44 (n)200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.3400.511.52+

Rotate screen for more detailsIncrease width for more details

← Zenuzolac
reduces riskZenuzolac
increases risk →

c19early.org

October 2026

Zenuzolac COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Kane (DB RCT)−200%3.00 · 0.32–28.3246 (n)44 (n)

Late treatment−200%3.00 · 0.32–28.3246 (n)44 (n)200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.34

All studies−200%3.00 · 0.32–28.3246 (n)44 (n)200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.3400.511.52+

Rotate screen for more detailsIncrease width for more details

← Zenuzolac
reduces riskZenuzolac
increases risk →

c19early.org

October 2026

Zenuzolac COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Kane (DB RCT)−200%3.00 · 0.32–28.32death46 (n)44 (n) Kane (DB RCT)−196%2.96 · 0.12–70.70death1/460/44 Kane (DB RCT)−205%3.05 · 0.13–72.79death1/420/44 Kane (DB RCT)−1%1.01 · 0.25–4.09no recov.46 (n)44 (n) Kane (DB RCT)−43%1.43 · 0.25–8.18no recov.3/462/44 Kane (DB RCT)48%0.52 · 0.05–5.56no recov.1/422/44 Kane (DB RCT)1%0.99 · 0.88–1.11hosp. time46 (n)44 (n) Kane (DB RCT)1%0.99 · 0.84–1.16hosp. time46 (n)44 (n) Kane (DB RCT)1%0.99 · 0.83–1.18hosp. time42 (n)44 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Zenuzolac
reduces riskZenuzolac
increases risk →